BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Moderna inks supply agreement with Gavi for up to 500 M vaccine doses

May 4, 2021 | News

34 million doses to begin delivery in the fourth quarter of 2021



US based firm Moderna, Inc. has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021.

Through this agreement, on behalf of the COVAX Facility, Gavi also retains the option to procure 466 million additional doses in 2022. All doses are offered at Moderna's lowest tiered price, in line with the company's global access commitments.

This agreement covers the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. The company is in discussions to allocate and supply to self-financing participants in the future.

COVAX is a global initiative co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.